Irradiated haploidentical donor leukocyte infusions as an adoptive immunotherapy strategy to induce host-versus-tumor effects

Tumori

Volumn 97, Issue 4, 2011, Pages 522-531

  Zhao, Shen ^a,b   Li, Jie Yu ^b   Zheng, Xiao Bin ^b   Peng, Feng ^b   Ye, Yun Bin ^b   Chen, Qiang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUJIAN PROVINCIAL TUMOR HOSPITAL   (China)

Author keywords

Cyclophosphamide; Immunotherapy; Mouse; Tumor

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CYTOKINE RELEASE; DONOR LYMPHOCYTE INFUSION; ENZYME ACTIVITY; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDY; IMMUNOCYTOTOXICITY; IN VIVO STUDY; LIVER CELL CARCINOMA; LYMPHOCYTE PROLIFERATION; MOUSE; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NONHUMAN; SINGLE DRUG DOSE; SPLEEN CELL; STRATEGIC PLANNING; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT; TUMOR VOLUME; UPREGULATION;

EID: 80053646107     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700418     Document Type: Article

References (27)

1. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M,WilmannsW: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76: 2462-2465, 1990.
2. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, Van de Donk NW, Van Oers MH, Cornelissen JJ, Schattenberg AV: The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood, 103: 4362-4364, 2004. (Pubitemid 38685385)
3. Porter DL, Connors JM, Van Deerlin VM, Duffy KM, McGarigle C, Saidman SL, Leonard DG, Antin JH: Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol, 17: 1234-1243, 1999. (Pubitemid 29162949)
4. Igietseme JU, Smith K, Simmons A, Rayford PL: Effect of gamma-irradiation on the effector function of T lymphocytes in microbial control. Int J Radiat Biol, 67: 557-564, 1995.
5. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol, 153: 1687-1696, 1994.
6. Muraoka S, Miller RG: Cells in murine fetal liver and in lymphoid colonies grown from fetal liver can suppress generation of cytotoxic T lymphocytes directed against their self antigens. J Immunol, 131: 45-49, 1983. (Pubitemid 13067087)
7. Waller EK, Boyer M: New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells. Bone Marrow Transplant, 25 (Suppl 2): S20-24, 2000. (Pubitemid 30433615)
8. Waller EK, Ship AM, Mittelstaedt S, Murray TW, Carter R, Kakhniashvili I, Lonial S, Holden JT, Boyer MW: Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. Blood, 94: 3222-3233, 1999. (Pubitemid 29512732)
9. Strair RK, Schaar D, Medina D, Todd MB, Aisner J, DiPaola RS, Manago J, Knox B, Jenkinson A, Senzon R, Baker C, Liesel D, Ciardella M, Kuriyan M, Rubin A, Lattime EC: Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma. J Clin Oncol, 21: 3785-3791, 2003. (Pubitemid 46606233)
10. Chen Q, Lin RB, Ye YB, Fan NF, Guo ZQ, Zhou ZF,Wang XJ, Chen MS, Chen SP, Li JY: The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report. Med Oncol, 27: 554-558, 2010.
11. Li XF, Chen Q, Ye YB, Fan LF, Chen MS, Li JY, Chen HQ, Chen SP, Zhou ZF: Effects of NKG2D and its ligands RAE-1 and H60 on graft-versus-tumor response. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 15: 160-164, 2007.
12. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R: Allogeneic cell therapy for relapsed leukemia after bonemarrow transplantation with donor peripheral blood lymphocytes. Exp Hematol, 23: 1553-1562, 1995. (Pubitemid 26034083)
13. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood, 87: 2195-2204, 1996. (Pubitemid 26086858)
14. Su X, Guo S, Zhou C,Wang D,MaW, Zhang S: A simple and effectivemethod for cancer immunotherapy by inactivated allogeneic leukocytes infusion. Int J Cancer, 124:1142-1151, 2009.
15. Lin H, Ye YB, Li XF, Chen Q: Graft-versus-tumor (GVT) effect induced by haploidentical transplantation in mice. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kanfu, 12: 456-460, 2008.
16. Luznik L, Fuchs EJ: Donor lymphocyte infusions to treat hematologicmalignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control, 9: 123-137, 2002. (Pubitemid 34457331)
17. Yu J, Tian R, Xiu B, Yan J, Jia R, Zhang L, Chang AE, Song H, Li Q: Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells. Int J Biol Sci, 5: 135-146, 2009.
18. Rosenberg SA, Dudley ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA, 101 (Suppl 2): 14639-14645, 2004. (Pubitemid 39346736)
19. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 105: 3051-3057, 2005.
20. Ikeda H, Chamoto K, Tsuji T, Suzuki Y,Wakita D, Takeshima T, Nishimura T: The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci, 95: 697-703, 2004. (Pubitemid 39335087)
21. Laurin D, Kanitakis J, Bienvenu J, Bardin C, Bernaud J, Lebecque S, Gebuhrer L, Rigal D, Eljaafari A: Allogeneic reaction induces dendritic cell maturation through proinflammatory cytokine secretion. Transplantation, 77: 267-275, 2004. (Pubitemid 38155757)
22. Rubio MT, Kim YM, Sachs T, Mapara M, Zhao G, Sykes M: Antitumor effect of donormarrowgraft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. Blood, 102: 2300-2307, 2003. (Pubitemid 37122413)
23. Lu Y, Waller EK: Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. Biol Blood Marrow Transplant, 15: 1347-1353, 2009.
24. Saito TI, Li HW, Sykes M: Invariant NKT cells are required for antitumor responses induced by host-versus-graft responses. J Immunol, 185: 2099-2105, 2010.
25. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, Proietti E: Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res, 13: 644-653, 2007. (Pubitemid 46225372)
26. Liu JY, Wu Y, Zhang XS, Yang JL, Li HL, Mao YQ, Wang Y, Cheng X, Li YQ, Xia JC, Masucci M, Zeng YX: Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother, 56: 1597-1604, 2007. (Pubitemid 47094389)
27. Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F: Importance of cyclophosphamide-induced by stander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest, 101: 429-441, 1998. (Pubitemid 28067341)